CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION
申请人:——
公开号:US20020077306A1
公开(公告)日:2002-06-20
This invention relates to chemically modified oligo-nucleotide conjugates that contain a complexing agent or complex that is bound by a connecting component to the oligonucleotides. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases. The oligonucleotide radical can bond specifically and with high bonding affinity to target structures and can thus produce a specific therapeutic or diagnostic effect by the bound complexing agent or complex.
CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES
申请人:SCHERING AKTIENGESELLSCHAFT
公开号:EP0777498A1
公开(公告)日:1997-06-11
[EN] CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES<br/>[FR] CONJUGUES CONSTITUES DE COMPLEXES METALLIQUES ET D'OLIGONUCLEOTIDES
申请人:SCHERING AKTIENGESELLSCHAFT
公开号:WO1996002274A1
公开(公告)日:1996-02-01
(EN) This invention relates to chemically modified oligonucleotide conjugates that contain a complexing agent or complex that is bound by a connecting component to the oligonucleotides. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases. The oligonucleotide radical can bond specifically and with high bonding affinity to target structures and can thus produce a specific therapeutic or diagnostic effect by the bound complexing agent or complex.(FR) L'invention concerne des conjugués d'oligonucléotides modifés chimiquement contenant un agent de formation de complexes ou un complexe lié par un consituant de liaison aux oligonucléotides. Dans ce cas, les oligonucléotides sont modifiés d'une manière empêchant ou au moins inhibant sensiblement la dégradation par des nucléases naturelles. Le radical oligonucléotidique peut se lier spécifiquement, avec une haute affinité de liaison, à des structures cibles, il peut par conséquent produire un effet thérapeutique ou diagnostique spécifique par l'agent de formation de complexes ou le complexe lié.
Morphy, J. Richard; Parker, David; Kataky, Ritu, Journal of the Chemical Society. Perkin transactions II, 1990, # 4, p. 573 - 585
作者:Morphy, J. Richard、Parker, David、Kataky, Ritu、Eaton, Michael A. W.、Millican, Andrew T.、et al.
DOI:——
日期:——
Antibody labelling with functionalised cyclam macrocycles
作者:J. Richard Morphy、David Parker、Rikki Alexander、Amarjit Bains、Alex F. Carne、Michael A. W. Eaton、Alice Harrison、Andrew Millican、Alison Phipps、Stephen K. Rhind、Richard Titmas、David Weatherby
DOI:10.1039/c39880000156
日期:——
Functionalised ‘cyclam’ macrocyclic ligands have been selectively attached to thiol residues on a monoclonal antibody and form kinetically inert complexes with Cu2+ and TcV.